Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Viewpoints: The promise and perils of prostate screening; Presidential candidates shy away from frank discussion of spending

After an exhaustive process, the U.S. Preventive Services Task Force has announced its final recommendation on PSA-based prostate cancer screening. It finds that the known harms of screening outweigh the potential benefits for men who have no cancer symptoms. It notes that all screening studies have demonstrated considerable harms associated with screening, but only one major study found evidence that screening saves lives -- and that study has some internal inconsistencies.

24 May 2012

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein -- but no one has known how that alteration promotes cancer growth. Now, Weill Cornell Medical College researchers have found that in these cancer cells, the 3-D architecture of DNA, wrapped up in a little ball known as a chromatin, is warped in such a way that a switch has been thrown on thousands of genes, turning them on or off to promote abnormal, unchecked growth. Researchers also found that new chromosomal translocations form, further destabilizing the genome.

23 May 2012

Federal task force recommends dropping routine prostate cancer test

The U.S. Preventive Services Task Force finds scant evidence that the PSA blood test saves lives and instead says unneeded treatment leads to serious problems, including impotence and incontinence.

23 May 2012

Article examines reasons why people are so reluctant to give up PSA test

The uproar that began last year when the U.S. Preventive Services Task Force stated that doctors should no longer offer regular prostate-cancer tests to healthy men continued this week when the task force released their final report. Overall, they stuck to their guns, stating that a blood test commonly used to screen for prostate cancer, the PSA test, causes more harm than good - it leads men to receive unnecessary, and sometimes even dangerous, treatments.

23 May 2012

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

23 May 2012

MCP enhances anti-cancer effects of two poly-botanical formulas

In a groundbreaking study, Modified Citrus Pectin (MCP), a highly researched natural compound enhanced the anti-cancer effects of two poly-botanical formulas.

23 May 2012

First Edition: May 22, 2012

Today's headlines include reports about a lawsuit brought by Catholic organizations against the Obama administration's contraception coverage rule and a new recommendation on PSA screening by the U.S. Preventive Services Task Force.

22 May 2012

LUGPA discredits recommendations by USPSTF to stop prostate cancer testing

The Large Urology Group Practice Association (LUGPA), representing more than 1,800 urologists, today discredited recommendations by the U.S. Preventive Services Task Force (USPSTF) to stop prostate cancer testing.

22 May 2012

USPSTF issues final recommendation statement against PSA testing

The Prostate Cancer Roundtable expressed deep disappointment today as the U.S. Preventive Services Task Force (USPSTF) issued its final recommendation statement against the use of prostate-specific antigen (PSA) testing in the detection of prostate cancer.

22 May 2012

Intermountain signs collaborative research agreement with Myriad

Intermountain Healthcare and Myriad Genetics today announced they have signed a collaborative research agreement. The purpose of this agreement is to perform research and validation studies on transformative molecular diagnostic tests being developed by Myriad in an effort to improve the care and treatments for patients at Intermountain and around the world.

22 May 2012

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Active Biotech and Ipsen today announced that recruitment to the global, pivotal, randomized, double-blind, placebo-controlled phase III study of tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC) has reached an inclusion of 600 patients, half of the planned accrual.

21 May 2012

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference.

21 May 2012

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Treatment of early stage prostate cancer can also result in improved quality of life for a subgroup of men who suffer from lower urinary tract symptoms (LUTS), according to an abstract of a Beth Israel Deaconess Medical Center-led study presented to the American Urological Association.

21 May 2012

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

21 May 2012

Study uncovers distinct subtype of prostate cancer

A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical College, the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute.

21 May 2012

Urologic conditions contribute to major economic burden in the U.S.

Urologic conditions like urinary tract infections, kidney stones, and prostate cancer are a major economic burden on Americans, resulting in health care costs of close to $40 billion annually, according to a newly released national report that charts the demographic and economic impact of urologic diseases in the U.S.

19 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

Promising updates in quest for early detection and treatments for lung cancer

LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is pleased to note promising updates in researchers' quest for early detection and treatments for lung cancer during May, Lung Cancer Hope Month.

18 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012

Prostate Cancer Risk Calculator offers men ‘individual risk assessment’

Men worried about prostate cancer have a new online resource, freely available, to help them assess their risk. The multi-step Prostate Cancer Risk Calculator, www.prostatecancer-riskcalculator.com*, has been created by the founders of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

18 May 2012

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Viewpoints: The promise and perils of prostate screening; Presidential candidates shy away from frank discussion of spending

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Federal task force recommends dropping routine prostate cancer test

Article examines reasons why people are so reluctant to give up PSA test

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MCP enhances anti-cancer effects of two poly-botanical formulas

First Edition: May 22, 2012

LUGPA discredits recommendations by USPSTF to stop prostate cancer testing

USPSTF issues final recommendation statement against PSA testing

Intermountain signs collaborative research agreement with Myriad

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Study uncovers distinct subtype of prostate cancer

Urologic conditions contribute to major economic burden in the U.S.

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Promising updates in quest for early detection and treatments for lung cancer

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Prostate Cancer Risk Calculator offers men ‘individual risk assessment’

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in